Windward Bio doses first patients in Phase II SIRIUS COPD trial

Harbour BioMed’s partner Windward Bio has dosed the first patients in the Phase II SIRIUS trial with SKB378 to treat COPD. The study aims to assess the safety, pharmacodynamics, pharmacokinetics and tolerability of HBM9378 for COPD. COPD causes severe flare-ups, hospitalisations, and lasting declines in lung function. Credit: NMK-Studio / Shutterstock.com. Harbour BioMed’s partner Windward Bio has dosed the first patients in the Phase II SIRIUS trial with HBM9378/WIN378 (SKB378), a fully human monoclonal antibody, to treat chronic obstructive pulmonary disease (COPD). The randomised, global, double-blind, placebo-controlled, dose-finding trial focuses on patients with COPD, a progressive and irreversible lung disease.…

Source: Clinical Trials Arena